© Reuters. FILE PHOTO: A vial containing the Moderna COVID-19 vaccine is seen at a temporary vaccination center of Swiss Medix health center as the spread of the coronavirus disease continues, in the Offene St. Jakob Kirche Reformed church in Zurich, Switzerland May
SEOUL (Reuters) – Shares in South Korean drug contract manufacturer Samsung (KS:) BioLogics rose as much as 5.2% in early Monday trade, after it agreed to fill-finish manufacture Moderna (NASDAQ:)’s COVID-19 vaccine.
The agreement was part of Moderna Inc and Novavax (NASDAQ:) Inc entering into a deal with the South Korean government to manufacture their COVID-19 vaccines.
The wider market was down 0.2% as of 0007 GMT.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment